| HOME >> MEDICINE >> TECHNOLOGY |
4.4.3 European Coagulation Market 106
4.4.4 Trends in POCT Coagulation Testing 106
4.4.4.1 Self-testing Coagulation Market 106
4.4.4.2 D-Dimer Testing 107
4.4.5 Point of Care Coagulation Testing Assay Market and Technology Trends 107
4.4.5.1 Point of Care Coagulation Testing Assay Market Trends 107
4.4.5.2 Point of Care Coagulation Testing Assay Technology Trends 108
4.4.5.3 Point of Care Coagulation Testing Assay Strategic Recommendations 108
4.5 Rapid Cardiac Markers 109
4.5.1 U.S. Market 109
4.5.2 European Market 111
4.5.3 Market Drivers and Restraints 113
4.5.3.1 Market Drivers 113
4.5.3.2 Market Restraints 113
4.5.4 Point of Care Cardiac Marker Testing Assay Market and Technology Trends
113
4.5.4.1 Point of Care Cardiac Marker Testing Assay Market Trends 113
4.5.4.2 Point of Care Cardiac Marker Testing Assay Technology Trends 114
4.5.4.3 Point of Care Cardiac Marker Testing Assay Strategic Recommendations 114
4.6 Drugs of Abuse Screening Testing 114
4.6.1 Acetaminophen 121
4.6.2 Tricyclic Antidepressants (TCAs) 122
4.6.3 Other Toxic Drugs 122
4.6.4 Drug Testing Selectivity 122
4.6.5 Methaqualone and Phencyclidine (PCP) 123
4.6.6 Tetrahydrocannabinol 123
4.6.7 Drug Panels by Toxidromes 123
4.6.8 Alcohol Testing 123
4.7 Urine Strips 124
4.8 Pregnancy Tests 127
4.9 Fecal Occult Blood 128
4.10 Hemoglobin Testing 129
4.11 Miscellaneous Rapid Tests 130
4.11.1 Estriol 130
4.11.2 Fetal Fibronectin (fFN) 131
4.11.3 H. pylori 131
4.11.4 Vaginal pH and Vaginitis 131
4.11.5 Bladder Cancer 132
4.11.6 Fetal Status 133
4.11.7 Heparin-induced Thrombocytopenia 133
4.12 Human Immunodeficiency Virus (HIV) 133
4.13 Cholesterol 140
4.14 Infectious Dise
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |